VRNA Key Statistics, Chart & Performance
The current stock price of VRNA is 106.91 USD. In the past month the price increased by 0.66%. In the past year, price increased by 227.19%.
VRNA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VRNA. When comparing the yearly performance of all stocks, VRNA is one of the better performing stocks in the market, outperforming 97% of all stocks.
VRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRNA. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VRNA Financial Highlights
Over the last trailing twelve months VRNA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 36.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.17% | ||
| ROE | -29.18% | ||
| Debt/Equity | 0.87 |
VRNA Forecast & Estimates
18 analysts have analysed VRNA and the average price target is 108.43 USD. This implies a price increase of 1.42% is expected in the next year compared to the current price of 106.91.
For the next year, analysts expect an EPS growth of 123.97% and a revenue growth 1008.75% for VRNA
VRNA Ownership
About VRNA
Company Profile
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Company Info
VERONA PHARMA PLC - ADR
3 More London Riverside
London SE1 2RE GB
CEO: David Zaccardelli
Employees: 209
Phone: 442032834200
VERONA PHARMA PLC - ADR / VRNA FAQ
Can you describe the business of VERONA PHARMA PLC - ADR?
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
What is the stock price of VERONA PHARMA PLC - ADR today?
The current stock price of VRNA is 106.91 USD. The price increased by 0.11% in the last trading session.
Does VERONA PHARMA PLC - ADR pay dividends?
VRNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of VRNA stock?
VRNA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for VRNA stock?
18 analysts have analysed VRNA and the average price target is 108.43 USD. This implies a price increase of 1.42% is expected in the next year compared to the current price of 106.91.
What is the expected growth for VRNA stock?
The Revenue of VERONA PHARMA PLC - ADR (VRNA) is expected to grow by 1008.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is VERONA PHARMA PLC - ADR worth?
VERONA PHARMA PLC - ADR (VRNA) has a market capitalization of 9.19B USD. This makes VRNA a Mid Cap stock.